A case report of Crohn's disease in a child treated with upadacitinib

Gui-Xian PAN; Qiu-Ping YANG; Xi-Mei YANG; Yao CAI; Si-Tao LI

doi:10.7499/j.issn.1008-8830.2508046

PDF(1077 KB)

Chinese Journal of Contemporary Pediatrics ›› 2026, Vol. 28 ›› Issue (3) : 342-345. DOI: 10.7499/j.issn.1008-8830.2508046

CASE REPORT

A case report of Crohn's disease in a child treated with upadacitinib

Gui-Xian PAN ¹ ,
Qiu-Ping YANG ¹ ,
Xi-Mei YANG ¹ ,
Yao CAI ¹ ,
Si-Tao LI ¹^,²

Author information +

History +

Abstract

A 12-year-old boy presented with recurrent abdominal pain for more than 5 months and a perianal mass for 10 days. Gastrointestinal endoscopy revealed multiple ulcers in the terminal ileum and colon, and Crohn's disease was diagnosed based on histopathology. The patient had atopic dermatitis and had previously received upadacitinib; after the diagnosis of Crohn's disease, upadacitinib was continued. During a total follow-up of 100 weeks, the patient maintained clinical remission without serious adverse reactions. This is the first report from China on upadacitinib treatment for pediatric Crohn's disease and provides guidance for its use in this population.

Key words

Crohn's disease / Upadacitinib / Long-term follow-up / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Gui-Xian PAN , Qiu-Ping YANG , Xi-Mei YANG , et al . A case report of Crohn's disease in a child treated with upadacitinib[J]. Chinese Journal of Contemporary Pediatrics. 2026, 28(3): 342-345 https://doi.org/10.7499/j.issn.1008-8830.2508046

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

[1]	Loftus EV, Panés J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn's disease[J]. N Engl J Med, 2023, 388(21): 1966-1980. DOI: 10.1056/NEJMoa2212728 . https://www.ncbi.nlm.nih.gov/pubmed/37224198 Cited in this article [1]

[2]

Peyrin-Biroulet

, Louis

, Loftus

, et al. Quality of life and work productivity improvements with upadacitinib: phase 2b evidence from patients with moderate to severe Crohn's disease[J]. Adv Ther, 2021, 38(5): 2339-2352. PMCID: PMC8107073. DOI: 10.1007/s12325-021-01660-7 .

https://www.ncbi.nlm.nih.gov/pubmed/33755884

Cited in this article [1]

[3]

D'Haens

, Panés

, Louis

, et al. Upadacitinib was efficacious and well-tolerated over 30 months in patients with Crohn's disease in the CELEST extension study[J]. Clin Gastroenterol Hepatol, 2022, 20(10): 2337-2346.e3. DOI: 10.1016/j.cgh.2021.12.030 .

https://www.ncbi.nlm.nih.gov/pubmed/34968730

Cited in this article [1]

[4]	Clement B, De Felice K, Afzali A. Indications and safety of newer IBD treatments in the older patient[J]. Curr Gastroenterol Rep, 2023, 25(7): 160-168. PMCID: PMC10209934. DOI: 10.1007/s11894-023-00874-9 . https://www.ncbi.nlm.nih.gov/pubmed/37227615 Cited in this article [1]

[5]

Paller

, Ladizinski

, Mendes-Bastos

, et al. Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the measure up 1, measure up 2, and AD up randomized clinical trials[J]. JAMA Dermatol, 2023, 159(5): 526-535. PMCID: PMC10099102. DOI: 10.1001/jamadermatol.2023.0391 .

https://www.ncbi.nlm.nih.gov/pubmed/37043227

Cited in this article [1]

[6]	Patruno C, Lauletta G, Pezzolo E, et al. Effectiveness and safety of upadacitinib for adolescents with atopic dermatitis in a real-world setting[J]. Clin Drug Investig, 2024, 44(8): 629-634. DOI: 10.1007/s40261-024-01382-y . https://www.ncbi.nlm.nih.gov/pubmed/39012535 Cited in this article [1]

[7]	Collen LV. Rapid clinical remission with upadacitinib in a pediatric patient with refractory Crohn's disease[J]. Inflamm Bowel Dis, 2023, 29(7): 1175-1176. DOI: 10.1093/ibd/izad048 . https://www.ncbi.nlm.nih.gov/pubmed/36933200 Cited in this article [1]

[8]	Spencer EA, Bergstein S, Dolinger M, et al. Single-center experience with upadacitinib for adolescents with refractory inflammatory bowel disease[J]. Inflamm Bowel Dis, 2024, 30(11): 2057-2063. PMCID: PMC12102471. DOI: 10.1093/ibd/izad300 . https://www.ncbi.nlm.nih.gov/pubmed/38134405

[9]	Liu Y, Song X, Xiang L, et al. Rapid remission with upadacitinib in a child with refractory Crohn's disease and ATM mutation: a case report[J]. Curr Ther Res Clin Exp, 2024, 101: 100756. PMCID: PMC11385748. DOI: 10.1016/j.curtheres.2024.100756 . https://www.ncbi.nlm.nih.gov/pubmed/39257480

[10]	Bousvaros A, Schmidt BAR, Kurtz M. Treatment of genital Crohn's disease with upadacitinib in a male child: a case report[J]. Gastroenterol Hepatol (N Y), 2023, 19(7): 401-403. PMCID: PMC10524414. https://www.ncbi.nlm.nih.gov/pubmed/37771618 Cited in this article [1]